We are excited to invite you to an exclusive webinar highlighting new findings from a recent The Lancet Psychiatry publication on VR-based therapy for auditory hallucinations in treatment-resistant schizophrenia.
This one-hour session will feature:
- 5 minutes - Welcome.
- 25 minutes – Presentation by Louise Birkedal Glenthoj, PI of the trial, sharing study outcomes and clinical insights.
- 15 minutes – HekaVR team showcasing their innovative VR setup and solution for delivering avatar therapy.
- 15 minutes – Open Q&A with the speakers and closing the session.
Summary:
The Challenge trial tested a new virtual reality therapy for people with schizophrenia who hear persistent voices. In VR, patients created and spoke with an avatar of their dominant voice. Compared to standard care, the therapy led to clear reductions in severity and frequency of voices—7 out of 10 patients reported symptom improvement, and 11 became completely free of voices. The treatment was generally safe, well-tolerated, and most patients completed it, showing immersive VR could be a promising new tool when medication alone isn’t enough.
